Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients

Cancer Immunology, Immunotherapy

Volumn 52, Issue 2, 2003, Pages 127-131

  Koukourakis, Michael I ^a   Ktenidou Kartali, Sophia ^a   Bourikas, George ^a   Kartalis, George ^a   Tsatalas, Costas ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Amifostine; Breast cancer; CD31; CD95; Lymphocyte; Radiotherapy

Indexed keywords

AMIFOSTINE; CD19 ANTIGEN; CD31 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FAS ANTIGEN; FLUOROURACIL; RADIOPROTECTIVE AGENT;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PROTECTION;

EID: 0037296515     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0342-y     Document Type: Article

References (34)

1. Louagie H, van Eijkeren M, Philippe J, Thierens H, de Ridder L (1999) Changes in peripheral blood lymphocyte subsets in patients undergoing radiotherapy. Int J Radiat Biol 75:767
2. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman J, Pecorelli S, Cannon M, Parham GP (2000) Effects of concurrent cisplatinum administration during radiotherapy vs radiotherapyq alone on the immune function of patients with cancer of the uterin cervix. Int J Radiat Oncol Biol Phys 48:997
3. Yamanaka R, Tanaka R, Yoshida S, Mori H, Takeda N, Satoh M (1993) Effects of ACNU and cranial irradiation on the mouse immune system. Neurol Med Chir 33:65
4. Koukourakis MI, Kourousis C, Kamilaki M, Koukouraki S, Giatromanolaki A, Kakolyris S, Kotsakis A, Androulakis N, Bahlitzanakis N, Georgoulias V (1998) Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer. 34:838
5. Reckzeh B, Merte H, Pfluger KH, Pfab R, Wolf M, Havemann K (1996) Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 14:1071
6. Kotsakis A, Sarra E, Peraki M, Eïukourakis MI, Apostolaki S, Souglakos J, Mavromanomakis E, Vlachonicolis J, Georgoulias V (2000) Docetaxel-induced lymphopenia in patients with solid tumors. A prospective phenotypic analysis. Cancer 89:1380
7. Pillai R, Balaram P, Chidambaram S et al (1990) Development of an immunological staging system to prognosticate disease course in malignant cervical neoplasia. Gynecol Oncol 37:200
8. Pupa SM, Bufalino R, Invernizzi AM, Andreola S, Rilke F, Lombardi L, Colnagli Menard S (1996) Macrophage infiltrate and prognosis in c-erbB-2 overexpressing breast carcinomas. J Clin Oncol 14:85
9. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL (1995) Loss of TAP-1 transport protein and MHC-class I molecules in metastatic compared to primary breast cancer. Cancer Res 55:5191
10. Koukourakis MI, Giatromanolaki A, Guddo F, Kaklamanis L, Vignola M, Kakolyris S, Turley H, Georgoulias V, Bonsignore G, Gatter KC, Harris AL (2000) c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer. J Immunother 23:104
11. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339
12. Koukourakis MI, Kyrias G, Kakolyris S, Kouroussis C, Frangiadaki C, Giatromanolaki A, Retalis G, Georgoulias V (2000) Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 18:2226
13. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101
14. Hartmann JT, von Vangerow A, Fels LM, Knop S, Stolte H, Kanz L, Bokemeyer C (2001) A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologus blood stem cell transplantation. Br J Cancer 84:313
15. Koukourakis MI, Giatromanolaki A, Kouroussis C, Kakolyris S, Sivridis E, Frangiadaki C, Retalis G, Georgoulias V (2002) Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. Int J Radiat Oncol Biol Phys 52:144
16. Stjernsward J, Jondal M, Vanky F, Wigzell H, Sealy R (1972) Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood indiced by irradiation for mammary carcinoma. Lancet 1:1352
17. Anderson JM (1972) T-cell depression and irradiation. Lancet 2:657
18. Wood SE, Campbell JB, Anderson JM, Kelly F (1974) Lymphocyte response after radiotherapy. Lancet 1:863
19. Provinciali M, Ciavattini A, Di Stefano G, Argentati K, Garzetti GG (1999) In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients. Life Sci 64:1525
20. Mason K, Staab A, Hunter N, McBride W, Petersen S, Terry N, Milas L (2001) Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 18:599
21. Koukourakis MI, Giatromanolaki A, Schiza S, Kakolyris S, Georgoulias V (1999) Concurrent twice a week docetaxel and radiotherapy. A dose escalation trial with immunological toxicity evaluation. Int J Radiat Oncol Biol Phys 43:107
22. Nagata S (1996). Fas-induced apoptosis, and diseases caused by its abnormality. Genes Cells 1:873
23. Coelho D, Holl V, Weltin D, Lacornerie T, Magnenet P, Dufour P, Bischoff P (2000) Caspase-3-like activity determines the type of cell death following ionizing radiation in MOLT-4 human leukaemia cells. Br J Cancer 83:642
24. Abdulkarim B, Sabri S, Deutsch E, Vaganay S, Marangoni E, Vainchenker W, Bongrand P, Busson P, Bourhis J (2000) Radiation-induced expression of functional fas lignat in EBV-positive human nasopharyngeal carcinoma cells. Int J Cancer 86:229
25. Sheard MA, Krammer PH, Zaloudik J (1999) Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95. Br J Cancer 80:1689
26. Ogawa Y, Nishioka A, Hamada N, Terashima M, Inomata T, Yoshida S, Seguchi H, Kishimoto S (1997) Expression of fas (CD95/APO-1) antigen induced by radiation therapy for diffused B-cell lymphoma: immunohistochemical study. Clin Cancer Res 3:2211
27. Herr I, Wilhelm D, Bohler T, Angel P, Debatin KM (1997) Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 16:6200
28. Demeure CE, Byun DG, Yang LP, Vezzio N, Delespesse G (1996). CD31 (PECAM-I) is a differentiation antigen lost during human CD4 T-cell maturation into Th1 or Th2 effector cells. Immunology 88:110
29. Piali L, Hammel P, Uherek C, Bachmann F, Gisler RH, Dunon D, Imfof BA (1995) CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol 130:451
30. Wakelin MW, Sanz MJ, Dewar A, Albelda SM, Larkin SW, Boughton-Smith N, Williams TJ, Nourshargh S (1996) An antiplatelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from messenteric microvessels in vivo by blocking the passage through the basement membrane. J Exp Med 184:229
31. Giatromanolaki A, Koukourakis M, Thedossiou D, Barbatis K, O'Byrne K, Harris AL, Gatter KC (1997) Comparative evaluation of angiogenesis assesment with anti-factor VIII and anti-CD31 immunostaining in non small cell lung cancer. Clin Cancer Res 3:2493
32. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, Papadimitriou C, Georgoulias V, Gatter KC, Harris AL, Koukourakis MI (1999) Combined role of angiogenesis, bc1-2 and p53 expression in the prognosis of colorectal cancer. Cancer 86:1421
33. Anastassiou G, Duensing S, Steinhoff G, Zorn U, Grosse J, Dallmann I, Kirchner H, Ganser A, Atzpodien J (1996) Platelet endothelial cell adhesion molecule-1 (PECAM-1): a potential prognostic marker involved in leukocyte infiltration of renal cell carcinoma. Oncology 53:127
34. Glover D, Negendank W, Delivoria-Papadopoulos M, Glick JH (1984) Alterations in oxygen transport following WR-2721. Int J Radiat Oncol Biol Phys 10:1565